215 related articles for article (PubMed ID: 38364321)
1. Reprogramming T-cell metabolism to enhance adoptive cell therapies.
Kates M; Saibil SD
Int Immunol; 2024 Apr; 36(6):261-278. PubMed ID: 38364321
[TBL] [Abstract][Full Text] [Related]
2. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
[TBL] [Abstract][Full Text] [Related]
3. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
4. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
5. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
Lim AR; Rathmell WK; Rathmell JC
Elife; 2020 May; 9():. PubMed ID: 32367803
[TBL] [Abstract][Full Text] [Related]
6. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
7. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
[TBL] [Abstract][Full Text] [Related]
8. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
10. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
11. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
[TBL] [Abstract][Full Text] [Related]
12. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
Front Immunol; 2022; 13():830292. PubMed ID: 35211124
[TBL] [Abstract][Full Text] [Related]
13. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
14. Immunometabolism in haematopoietic stem cell transplantation and adoptive cellular therapies.
Braverman EL; Waltz G; Byersdorfer CA
Curr Opin Hematol; 2020 Nov; 27(6):353-359. PubMed ID: 33003083
[TBL] [Abstract][Full Text] [Related]
15. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
16. The potential and promise for clinical application of adoptive T cell therapy in cancer.
Li Y; Zheng Y; Liu T; Liao C; Shen G; He Z
J Transl Med; 2024 May; 22(1):413. PubMed ID: 38693513
[TBL] [Abstract][Full Text] [Related]
17. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity.
Zhang S; Zhang X; Yang H; Liang T; Bai X
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189022. PubMed ID: 37993001
[TBL] [Abstract][Full Text] [Related]
18. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment.
Moinuddin A; Poznanski SM; Portillo AL; Monteiro JK; Ashkar AA
Immunol Rev; 2024 May; 323(1):19-39. PubMed ID: 38459782
[TBL] [Abstract][Full Text] [Related]
19. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.
Vanichapol T; Chutipongtanate S; Anurathapan U; Hongeng S
Biomed Res Int; 2018; 2018():1812535. PubMed ID: 29682521
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Cai F; Zhang J; Gao H; Shen H
Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]